Friday, 6 November 2026European Markets

SOLVAC NOM(RETAIL), SOLVAY, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Chemicals Industry.

Loading stream...

(vianews) - solvac nom(retail) (solv.br) is among this list of stock assets with the highest dividend rate and return on equity on the chemicals industry.

financial asset price forward dividend yield return on equity
solvac nom(retail) (solv.br) €113.00 4.79% 18.46%
solvay (solb.br) €105.40 3.62% 19.82%
robertet (rbt.pa) €876.00 0.88% 14.34%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. solvac nom(retail) (solv.br)

4.79% forward dividend yield and 18.46% return on equity

solvac s.a. operates as an advanced materials and specialty chemicals company in belgium. the company offers specialty polymers, composite materials, soda ash, peroxides, and silica. solvac s.a. was incorporated in 1983 and is headquartered in brussels, belgium.

earnings per share

as for profitability, solvac nom(retail) has a trailing twelve months eps of €-14.6.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.46%.

volatility

solvac nom(retail)'s last week, last month's, and last quarter's current intraday variation average was a negative 0.74%, a negative 0.15%, and a positive 1.40%.

solvac nom(retail)'s highest amplitude of average volatility was 1.34% (last week), 1.46% (last month), and 1.40% (last quarter).

more news about solvac nom(retail).

2. solvay (solb.br)

3.62% forward dividend yield and 19.82% return on equity

solvay sa provides advanced materials and specialty chemicals worldwide. it operates through four segments: materials, chemicals, solutions, and corporate & business services. the materials segment offers specialty polymers, including aromatic polymers, high barrier polymers, and fluoropolymers for the electronics, automotive, aircraft, and healthcare industries; and composite materials for aerospace engineered materials market. the chemicals segment produces and sells soda ash and sodium bicarbonate primarily to the flat and container glass industries, as well as for use in detergents, pharmaceutical, and feed and food industries; hydrogen peroxide for use primarily in the paper industry to bleach pulp, as well as chemicals, electronics, food, mining, and environment; and dispersible silica for tire manufacturers; and solvent solutions, specialty phenols, polyamide derivatives and smart, functional, and sustainable yarns and polymers. the solutions segment offers specialty chemicals for agro, home and personal care, coatings, and industrial markets; technology solutions in specialty mining reagents, phosphine-based chemistry, and solutions for the stabilization of polymers; fluorine and rare-earth formulations for automotive, electronics, agrochemical, and construction applications; and vanillin for the flavors and fragrances industries, as well as synthetic intermediates used in pharmaceuticals, agrochemicals, and electronics. this segment also provides friction reducers, gelling agents, emulsion breakers, surfactants, inhibitors, cementing additives, and biocides for upstream oilfield chemicals sector, as well as sodium hypophosphite for metal plating and other applications. the corporate & business services segment provides energy and other business services. the company was founded in 1863 and is headquartered in brussels, belgium.

earnings per share

as for profitability, solvay has a trailing twelve months eps of €-9.33.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.82%.

volume

today's last reported volume for solvay is 29445 which is 85.11% below its average volume of 197763.

dividend yield

according to morningstar, inc., the next dividend payment is on jan 16, 2023, the estimated forward annual dividend rate is 3.89 and the estimated forward annual dividend yield is 3.62%.

earnings before interest, taxes, depreciation, and amortization

solvay's ebitda is 0.81.

more news about solvay.

3. robertet (rbt.pa)

0.88% forward dividend yield and 14.34% return on equity

robertet sa produces and sells perfumes, aromas, and natural products. the company operates in three segments: raw materials, fragrances, and flavors. it also produces organic essential oils and active ingredients. the company operates in north america, europe, the asia pacific, south america, caribbean, africa, and the middle east. robertet sa was founded in 1850 and is headquartered in grasse, france.

earnings per share

as for profitability, robertet has a trailing twelve months eps of €21.87.

pe ratio

robertet has a trailing twelve months price to earnings ratio of 40.05. meaning, the purchaser of the share is investing €40.05 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.34%.

more news about robertet.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com